1. Extended duration chemoprophylaxis for venous thromboembolism following abdominopelvic oncologic surgery
- Author
-
John Holtrop, Ali Jawad, John J. Kanitra, and Richard Berri
- Subjects
Male ,medicine.medical_specialty ,medicine.drug_class ,Low molecular weight heparin ,030204 cardiovascular system & hematology ,Chemoprevention ,03 medical and health sciences ,Postoperative Complications ,0302 clinical medicine ,Clinical Protocols ,Surgical oncology ,medicine ,Humans ,Thrombophilia ,030212 general & internal medicine ,Medical prescription ,Pelvic Neoplasms ,Retrospective Studies ,Duration of Therapy ,business.industry ,Anticoagulants ,Venous Thromboembolism ,Hematology ,Heparin, Low-Molecular-Weight ,Middle Aged ,medicine.disease ,United States ,Surgery ,Pulmonary embolism ,Treatment Adherence and Compliance ,Venous thrombosis ,Abdominal Neoplasms ,Surgical Procedures, Operative ,Cohort ,Chemoprophylaxis ,Female ,Cardiology and Cardiovascular Medicine ,business ,Cohort study - Abstract
Venous thromboembolism (VTE), including deep venous thrombosis and pulmonary embolism, is the most common cause of 30-day morbidity in oncology patients following surgery due to their hypercoagulable state. To combat this, VTE prophylaxis with anticoagulation extending beyond hospital discharge, termed extended duration chemoprophylaxis (EDCP), has been proposed, with the most recent guidelines recommending 28 post-operative days of EDCP. However, the literature has demonstrated poor compliance to these recommendations. We extended the duration of EDCP to 28 days post hospital discharge, effectively creating a standard discharge prescription for all surgical oncology patients. Our aim is to assess our EDCP protocol on patient compliance and VTE rate following major oncologic resection. We performed a retrospective, single institution, cohort study that involved chart review and telephone survey on patients who underwent major open abdominopelvic oncologic resection. A total of 130 patients were included; 60 received EDCP and 68 did not. VTE rate for the EDCP cohort was 0% and 7.4% for the non-EDCP cohort (p = 0.04). 85% of patients were fully compliant with EDCP. No bleeding related complications with EDCP were identified. Our data is consistent with prior literature in demonstrating a lower VTE rate with EDCP without an increase in bleeding related complications and we have demonstrated that it is possible to achieve a high rate of patient compliance with EDCP.
- Published
- 2019